Literature DB >> 10408711

Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma.

H Imamura1, S Haga, T Shimizu, O Watanabe, T Kajiwara, M Aiba.   

Abstract

The prognostic significance of the proliferative activities in intraductal components and invasive foci was investigated using 157 cases of invasive ductal breast carcinoma in which intraductal components predominated. Proliferative activity was expressed as the number of MIB1-positive nuclei per 1000 cancer cells in the most active areas of intraductal components (MLI-DCIS) or invasive foci (MLI-INV). MLI-DCIS correlated closely with MLI-INV (r = 0.710, 95% confidence interval, 0.623-0.780; P < 0.0001). Both MLI-DCIS and MLI-INV were related to oestrogen receptor (ER) (P = 0.0006, P = 0.0028 respectively), grade of invasive tumour (P < 0.0001, P < 0.0001 respectively) and classification of intraductal components (P < 0.0001, P < 0.0001 respectively). In the univariate disease-free survival analysis, both MLI-DCIS and MLI-INV were found to be significant (P < 0.0001, P = 0.0003 respectively). However, in node-negative cases, only MLI-DCIS was significant (P = 0.0416). Multivariate analysis revealed that MLI-DCIS was significant not only in all cases, but also in node-negative cases (P = 0.0223, P = 0.0426 respectively), whereas MLI-INV was not. These findings indicate that MIB1-determined proliferative activity of intraductal components is a significant prognostic determinant of invasive ductal breast carcinoma in which intraductal components predominate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408711      PMCID: PMC2362174          DOI: 10.1038/sj.bjc.6690029

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

Review 1.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

2.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

3.  Cell kinetics of histologic variants of in situ breast carcinoma.

Authors:  J S Meyer
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

4.  Nucleolar organizer regions relate to growth fractions in human breast carcinoma.

Authors:  W A Raymond; A S Leong
Journal:  Hum Pathol       Date:  1989-08       Impact factor: 3.466

5.  Thymidine labeling index and Ki-67 growth fraction in lesions of the breast.

Authors:  O W Kamel; W A Franklin; J C Ringus; J S Meyer
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

6.  Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy.

Authors:  J M Kurtz; J Jacquemier; R Amalric; H Brandone; Y Ayme; D Hans; C Bressac; J Roth; J M Spitalier
Journal:  Cancer       Date:  1990-04-15       Impact factor: 6.860

7.  The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ).

Authors:  S K Gupta; A G Douglas-Jones; N Fenn; J M Morgan; R E Mansel
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

8.  Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast.

Authors:  J F McGurrin; M I Doria; P J Dawson; T Karrison; H O Stein; W A Franklin
Journal:  Cancer       Date:  1987-05-15       Impact factor: 6.860

9.  Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit.

Authors:  B Lloveras; S Edgerton; A D Thor
Journal:  Am J Clin Pathol       Date:  1991-01       Impact factor: 2.493

10.  The impact of tumor size and histology on local control after breast-conserving therapy.

Authors:  H Bartelink; J H Borger; J A van Dongen; J L Peterse
Journal:  Radiother Oncol       Date:  1988-04       Impact factor: 6.280

View more
  2 in total

1.  Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia.

Authors:  Marta Santisteban; Carol Reynolds; Emily G Barr Fritcher; Marlene H Frost; Robert A Vierkant; Stephanie S Anderson; Amy C Degnim; Daniel W Visscher; V Shane Pankratz; Lynn C Hartmann
Journal:  Breast Cancer Res Treat       Date:  2009-09-23       Impact factor: 4.872

Review 2.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.